Moreover, the farnesoid X receptor (FXR), involved in bile acid regulation, has been identified as a potential therapeutic target for IBD, with FXR agonists showing protective effects in mouse models of chemically induced colitis [16,27]. This evidence concerns the gene NR1H4 and colitis.